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Abstract
Background—The QT interval is a phase of the cardiac cycle that corresponds to action 
potential duration (APD) including cellular repolarization (T-wave). In both clinical and 
experimental settings, prolongation of the QT interval of the electrocardiogram (ECG) and related 
proarrhythmia have been so strongly associated that a prolonged QT interval is largely accepted as 
surrogate marker for proarrhythmia. Accordingly, drugs that prolong the QT interval are not 
considered for further preclinical development resulting in removal of many promising drugs from 
development. While reduction of drug interactions with hERG is an important goal, there are 
promising means to mitigate hERG block. Here, we examine one possibility and test the 
hypothesis that selective inhibition of the cardiac late Na current (INaL) by the novel compound 
GS-458967 can suppress proarrhythmic markers.
Methods and results—New experimental data has been used to calibrate INaL in the Soltis-
Saucerman computationally based model of the rabbit ventricular action potential to study effects 
of GS-458967 on INaL during the rabbit ventricular AP. We have also carried out systematic in 
silico tests to determine if targeted block of INaL would suppress proarrhythmia markers in 
ventricular myocytes described by TRIaD: Triangulation, Reverse use dependence, beat-to-beat 
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Instability of action potential duration, and temporal and spatial action potential duration 
Dispersion.
Conclusions—Our computer modeling approach based on experimental data, yields results that 
suggest that selective inhibition of INaL modifies all TRIaD related parameters arising from 
acquired Long-QT Syndrome, and thereby reduced arrhythmia risk. This study reveals the 
potential for adjunctive pharmacotherapy via targeted block of INaL to mitigate proarrhythmia risk 
for drugs with significant but unintended off-target hERG blocking effects.
Keywords
Long-QT Syndrome; GS-458967; Late Na current; Proarrhythmia
1. Introduction
Cardiotoxicity is a common risk for drugs in development, often manifesting as prolongation 
of the QT interval in the ECG and an increased likelihood for life-threatening ventricular 
arrhythmias [1,2,3]. QT interval prolongation typically arises from hERG block in 
ventricular myocytes and hERG interaction must be analyzed for all drug candidates to 
determine their potential for proarrhythmia [4]. A limitation of this approach is that many 
potentially useful drugs are eliminated early in the drug discovery process and development 
because they block hERG and thereby may cause acquired Long-QT Syndrome. Numerous 
drugs with potential for high therapeutic value never make it to the market because of their 
hERG positive signal. Here we consider an alternative approach that involves addition of an 
additional drug that selectively blocks late Na current (INaL) in order to “cancel” the hERG 
blocking effect. This approach, if useful, may be warranted in instances where a hERG 
positive therapy is uniquely indicated for disease and no alternative therapies exist.
The exploration of adjunctive therapy to mitigate drug side effects is with strong precedent 
[5,6,7]. A longstanding example can be found in effective antiarrhythmic drugs, which while 
categorized by their primary mechanism of action, exhibit off-target effects that apparently 
mitigate proarrhythmia risk. Included in this group is the most effective therapeutic for 
treating cardiac ventricular arrhythmias, amiodarone, a dirty drug whose multiple off-target 
effects likely underlie its efficacy. Here we try to extend this idea to adjunctive therapy 
design to promote the concept of “virtuous promiscuity” [8].
In this study we explore the basis for a novel adjunctive therapy aimed at mitigating acquired 
Long-QT as associated arrhythmia risk by pharmacological targeting of late Na current 
(INaL) using GS-458967, a potent and selective inhibitor of this current [9]. The first studies 
on the preclinical compound GS-458967 in 2013 showed potent selective targeting of INaL 
(GS-458967, IC50 for INaL = 130 nM, compared to Kd for tonic block of peak INa = 1500 
μM [9]) allowing for specific therapeutic inhibition and study of the physiological and 
pathological role for INaL in the heart.
We evaluated arrhythmia vulnerability by integrating data-based drug channel models into 
virtual ventricular myocyte and tissue models. On this basis we can provide predictions of 
emergent drug effects that modify individual elements of the TRIaD. This approach yielded 
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novel and potentially important insights into the proarrhythmia markers at the myocyte 
and/or tissue scales. Thus, it is based on the fundamental biophysical and molecular 
pharmacological mechanisms underlying drug induced arrhythmia and their influence on 
electrophysiological parameters. Gaining reliable insights that inform arrhythmia risk is the 
first necessary step that must be taken to ultimately lead to development of specific in silico 
screening test for both assessing risk and then implementing practical risk reduction 
measures.
Our model predictions illustrate that selective pharmacological targeting of INaL by 
inhibiting this current using GS-458967 improves all TRIaD related parameters in acquired 
Long-QT syndrome and consequently reduces arrhythmia risk.
2. Methods
2.1. Experimental methods
2.1.1. Recordings of late INa and action potentials using whole-cell patch-
clamp technique—The conventional whole-cell configuration of patch clamp technique 
was used to record late INa in voltage-clamp mode and action potentials (APs) in the current-
clamp mode. All whole-cell data were acquired using a Multiclamp 700B amplifier with 
pClamp 10.2 software (Molecular Devices, Sunnyvale, CA). Data was analyzed using 
pClampfit 10, Microcal Origin 8 (OriginLab Corporation, Northampton, MA), and 
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA) software programs. Patch 
pipettes were pulled from borosilicate glass (World Precision Instruments, Sarasota, FL) 
using a DMZ Universal Puller (Dagan Corporation, Minneapolis, MN). Current-clamp 
experiments were performed at 36 ± 1 °C using a temperature controlling system (TC-334B, 
Warner Instruments, Hamden, CT), whereas, the voltage-clamp experiments were done at 22 
± 1 °C. In all experiments, after a gigaseal was established in the whole-cell configuration, 
5–10 min was allowed for stabilization before the experimental protocol was started.
In recordings of INa, myocytes were superfused with bath solution containing (in mM): 135 
NaCl, 4.6 CsCl, 1.8 CaCl2, 1.1 MgSO4, 10 HEPES and 10 glucose supplemented with 
nitrendipine at a final concentration of 10 μM. The pH was adjusted to 7.4 with NaOH. The 
patch pipette resistances varied from 1.5–2 MΩ when they were filled with an internal 
solution containing (in mM): 120 aspartic acid, 20 CsCl, 1 MgSO4, 4 ATPNa2, 0.1 GTPNa3 
and 10 HEPES. The pH was adjusted to 7.3 with CsOH. Late INa was recorded during a 
1500 msec ramp voltage-clamp command starting from −90 mV and depolarizing to 0 mV 
once every 20 s. Late INa was measured as the maximum inward current during each ramp 
depolarization.
For microelectrode intracellular recordings of action potentials (APs), myocytes were 
superfused with bath solution containing (in mM): 140 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 
0.33 NaH2PO4, 5 HEPES and 7.5 glucose. The pH was adjusted to 7.4 with NaOH. Pipette 
resistances were in the range of 2–2.5 MΩ when using an internal solution containing (in 
mM) the following: 60 K aspartate, 80 KCl, 8 NaCl, 5 Mg-ATP, 0.25 Tris-GTP, and 5 
HEPES was used. The pH was adjusted to 7.3 with KOH. APs were elicited by 3–3.5 ms 
depolarizing current pulses adjusted to approximately 1.5 time the threshold and applied 
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every 5 s (0.2 Hz). The APD was measured at 90% (APD90) of full repolarization. Ten 
consecutive AP recordings were averaged for each experimental condition.
2.2. Simulation methods
2.2.1. Cellular simulations—A rabbit cardiac myocyte model was chosen in this study to 
align with the rabbit ventricular myocytes experimental data - unpublished and from [9]. The 
Soltis-Saucerman cardiac cell model [28] was modified as follows: The INa channel was 
replaced with Markov model described below and with full parameters in the accompanying 
supplement. The Na channel model structure was based on previously published models 
[11,12]. Recognizing that cardiac myocytes exhibit substantial variability in both current and 
action potential amplitudes and morphologies [13], we then empirically tuned the Ca2+ and 
K+ current amplitudes to simultaneously recapitulate a representative rabbit experimental 
current data [14,15,16] and action potential duration in experiments [9] are shown in Table 
1.
2.3. Optimization procedure for rabbit sodium channel
A computational Markov model of the drug-free (control) and GS-458967 drug channel 
interaction was formulated via numerical optimization from experimentally derived rate 
constants as previously described [11,17]. Five pacing protocols were optimized: steady 
state availability at test potentials from −130 mV to −50 mV followed by depolarization to 
−35 mV, steady state activation (the holding potential was −120 mV and the testing 
potentials ranged from −60 to 20 mV in 5-mV steps) [18], recovery from inactivation at a 
holding potential of −100 mV [18], INa time course current [9], and ramp pulses from Gilead 
Sciences, Inc. (Please see the section above on Recordings of late INa and action potentials 
using whole cell patch-clamp technique).
A cost function for each protocol was defined as the sum of squared differences between 
experiment and simulation. The total cost function (sum of the individual protocol errors) 
was then minimized and converged when a tolerance of 0.01 for the change of the cost 
function and 0.01 for the change in parameters was achieved.
All rate constants were allowed to change during the optimization. Post-optimization and 
Initial values are shown in Online Tables I and II, respectively.
2.4. Parameter optimization for drug-bound model
Simulations of GS-458967 dose-dependent effects on late Na current were optimized to fit 
the experimentally measured late Na+ current with GS-458967 concentrations of 0.03, 0.1, 
0.3 and 1 μM. The drug-bound rate constants (αx2, α13n, α_22, β_33, Kon, Kinactive, 
Kclosed) were optimized to fit the experimentally measured late Na+ current with GS-458967 
concentrations of 0.03, 0.1, 0.3, 1 μM and 10 μM, and the peak Na+ value at 10 μM (Fig. 
3A). The optimized rate constants are shown in Online Table IV. Because GS-458967 is 
highly non-basic and cannot be protonated at physiological pH, the post-optimization values 
(αx2, α13n, α_22, β_33, Kon, Kinactive, Kclosed) are shown in Online Tables III, and initial 
guesses are shown in Online Tables IV.
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2.5. Introduction of variability in the cellular model to create cell populations
Simulated single action potentials (APs) were recorded at the 500th paced beat (BCL = 1000 
ms). We have also simulated a cell ‘population’ by randomly varying the amplitude of 
maximal conductances for INa, ICaL, IKs, IKr, IK1, Ito, INaK, INaCa to within 10% (Fig. 3B) of 
their nominal values in the rabbit ventricular myocyte model, as is done in standard 
sensitivity analysis ([19,20,21]). This approach allowed for efficient analysis of 100 distinct 
cell action potentials. APD90 was calculated at 1 Hz for each case. These simulated myocyte 
properties were compared to distinct experimental data sets #1 (blue asterisks) and #2 (red 
circles) as shown in Fig. 3.
The numerical method used for updating the voltage was forward Euler. All the simulations 
were encoded in C/C++ and run on Mac Pro 3.06 GHz 12-Core computers. Numerical 
results were visualized using MATLAB R2014a by The Math Works, Inc.
2.6. Simulated effects of ATX-II
We have also simulated a ‘population’ of 100 cells by randomly varying the amplitude of 
maximal conductances as in Fig. 3B. APD90 was calculated at 0.2 Hz for each case in Fig. 5.
In Fig. 6B and C, 1D cables were first paced at 1 Hz for 200 beats with simulated ATX-II 
effects only, added GS-458967 for next 10 beats at 1 Hz (s1) followed by a pause (3000 ms), 
and then applied a premature beat (s2).
2.7. Simulation of TRIaD in dofetilide and drug-free models
To simulate effects of dofetilide, we replaced the IKr channel with our previously published 
Markov model [22]. For the TRIaD simulations, simulations were conducted as follows: 
First, Triangulation was calculated as the repolarization time from APD30 to APD90 from 
1000 simulated cell with noise currents. Reverse-use-dependence was measured APD90 at 
steady state for each pacing cycle length (from 3 Hz to 0.5 Hz) and APD adaptation curves 
were constructed. Instability was simulated by applying small amplitude inward currents 
randomly between −0.1 to −0.2 pA/pF for 50 ms over the course of the action potential 
plateau at a pacing cycle length = 1000 ms. A small inward current was also applied 
randomly in time between 10 to 210 ms on the plateau phase for 1000 beats. We modeled 
beat-to-beat APD variability by adding noise currents into membrane potential calculations, 
and simulated 1000 cells action potentials. Using the equation from [23],
Where n is N(0,1) is a random number from a Gaussian distribution, and Δt is the time step. 
ξ is the diffusion coefficient, which is the amplitude of noise. In Fig. 7, ξ was set to 0.32 
based on [23]. The noise current was generated and applied to membrane potential Vt 
throughout the whole simulated time course.
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2.8. Transmural fiber simulations
The in silico transmural fiber was composed of 165 ventricular cells (Δx = Δy = 100 μm) 
connected by resistances to simulate gap junctions [28]. The fiber contains an endocardial 
region and epicardial region, which shown a linear decreased in APDs [24,25]. In the model, 
GtoSlow was monotonically increased from 0.0615 to 0.078, and GtoFast was linearly 
increased from 0.0095 to 0.026. The fiber was paced at BCL = 1000 ms for 200 beats. The 
stimulus is applied to the first cell.
2.9. ECG computation
Extracellular unipolar potentials (Φe) generated by the fiber in an extensive medium of 
conductivity σe, were computed from the transmembrane potential Vm using the integral 
expression as in Gima and Rudy [26]:
In one-dimension:
In two-dimension:
r=[(x−x′)2 + (y−y′)]1/2 where ∇V is the spatial gradient of Vm, a is the radius of the fiber, σi 
is the intracellular conductivity, σe is the extracellular conductivity, and r is the distance 
from a source point (x, y, z) to a field point (x′, y′, z′). Φe was computed at an “electrode” 
site 2.0 cm away from the distal end along the fiber axis.
2.10. Transmural tissue simulations
We simulated a heterogeneous cardiac tissue assuming a 500 by 500 component grid Δx = 
Δy = 100 μm. This tissue was assumed to contain an endocardial region and epicardial 
region, with a linear decrease in APDs [24,25]. All ion channel conductances and gap-
junctions parameters are same as in the one-dimensional simulations. Current flow is 
described by the following equation:
Where V is the membrane potential, x and y are distances in the longitudinal and transverse 
directions, respectively, Dx and Dy are diffusion coefficients in the x and y directions. Istim is 
500 mA/cm2 for 1 ms. We also incorporated anisotropic effects by setting Dx and Dy such 
that the ratio of conduction velocity is 1:2 [27].
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This ventricular tissue segment was first paced for 200 beats (S1) at BCL = 1000 ms on the 
entire length of one side of tissue. A premature stimulus (S2) was then delivered at 330 ms 
in control case (A) after S1 in a 2.5 cm × 2.5 cm area on the top edge of the endocardial 
region. (B) In ATX-II case, S2 paced at 450 ms, and at 465 ms in Dofetilide case (C) after 
S1 in a 2.5 cm × 2.5 cm area on the top edge of the endocardial region. With GS-458967 
applications, S2 was applied at 420 ms in ATX-II (D) and at 430 ms (E) in Dofetilide cases 
(Fig. S2).
3. Results
The starting point for this study compared the simulated main currents and Ca2+ transient in 
the Soltis-Saucerman rabbit ventricular action potential model [28] during the AP to those 
recorded experimentally from individual rabbit ventricular myocytes (Fig. 1A–F). Next the 
Soltis-Saucerman model parameters for the maximum conductances for Ca2+ and K+ 
currents were tuned to match the experimental data from rabbit ventricular myocytes 
[14,15,16] including action potential durations [9]. Following these minor adjustments, the 
output of the model showed good agreement with the experimentally recorded currents.
We next modeled the rabbit ventricular Na+ current by re-optimizing the model parameters 
described in Moreno et al. [11] to reproduce the time-course and kinetics of INa that were 
experimentally recorded in rabbit ventricular myocytes patch clamping experiments. Fig. 2 
shows the adjusted, post-optimized, model-generated INa (blue lines) superimposed on 
experimental records (black symbols). Fig. 2A shows the superimposition of model and 
experimentally generated voltage dependent activation curves. Panel (B) shows the steady-
state Na+ channel availability (inactivation) relationship. Panel (C) shows the recovery time 
course of current (or reactivation) at −100 mV generated using a standard double pulse 
voltage clamp protocol. The time-course of INa is depicted in at low and high gain 
normalized to the peak INa value (panels D and E, respectfully). Panel F shows INa generated 
in response to a slow depolarizing voltage clamp ramp protocol. All protocols that are 
illustrated in the figure panels are described in detail in the Methods and Simulation methods 
section. It is interesting to note that rabbit ventricular myocytes exhibit a much smaller late 
INa component measured during a square wave voltage depolarizing pulse, when compared 
to the current measured in guinea pig ventricular myocytes [12].
3.1. Concentration-dependent reduction in INaL and APD by GS-458967
GS-458967 selectively inhibits endogenous INaL and causes concentration-dependent 
shortening of APD in ventricular myocytes [9,29,30]. Two independent experimental data 
sets from rabbit ventricular myocytes have been used as the basis for our model optimization 
to simulate the effects of GS-458967 on experimental data for rabbit INaL during the AP and 
on APD. The blue asterisks indicate previously published experimental data set #1 [9], and 
red circles are from our new (unpublished) experimental data set #2. We incorporated our 
calibrated rabbit ventricular Na+ channel model from Fig. 2 into the Soltis-Saucerman rabbit 
ventricular model of the cardiac ventricular action potential and then optimized the drug 
model parameters to fall within the independent experimental data sets. The results are 
shown in Fig. 3. Panel 3A shows the simulated effects of a 10-fold changes in concentrations 
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of GS-458967 and selective INaL block during the rabbit AP. The model accurately predicts 
the marked concentration-dependent shortening of the APD observed experimentally. Note 
that reduction of the large transient endogenous INapeak in the optimized model simulations 
is minimal even after a very high concentration of GS-458967 (10 μM). This was also 
observed experimentally in rabbit ventricular myocytes (compare blue open square to black 
open triangle). The selectivity for block of INaL compared to INapeak was a key goal in the 
drug discovery process that resulted in selection of GS-458967 as a potential candidate 
compound.
Fig. 3B shows a model prediction of the concentration dependence of the simulated effects 
of GS-458967 on the APDs in a rabbit ventricular myocyte population. These data were 
tracked in a population of 100 virtual myocytes generated by randomly varying the 
amplitude of maximal conductances for INa, ICaL, IKs, IKr, IK1, Ito, INaK, INaCa (to within (±) 
10% of their nominal values in the rabbit ventricular myocyte model) prior to the upstroke of 
each action potential. APD90 was calculated for each AP at a steady pacing frequency of 1 
Hz. Note that the simulated APD90 variability falls well within the range of experimentally 
recorded APD90 from both data set #1 (blue asterisks) and data #2 (red circles).
Fig. 4A shows the simulated time-course of the rabbit AP waveform. These results reveal the 
concentration-dependent effects of GS-458967 on rabbit ventricular repolarization. Panel B 
shows the corresponding dose-dependent effects of GS-458967 on the time-course of the 
endogenous INaL. It is notable that although INaL in the rabbit ventricular myocyte is very 
small in response to voltage clamp square wave depolarizing pulses (Fig. 2E), there is a 
detectable INaL throughout the plateau of the AP. Note also that INaL slowly increases during 
repolarization as expected from the progressively increasing electrochemical driving force.
3.2. GS-458967 normalizes drug induced APD prolongation
Our experimental data show that GS-458967 is very effective in reversing APD prolongation 
by agents/toxins that selectively enhance INaL (e.g. ATX-II). We used these data as a basis 
for comparisons for the computational model predictions. Specifically, we tested whether the 
selected drug concentrations would have similar effects when experimental data was 
compared to the model predictions, thereby acting as a model validation test and providing a 
basis for using the model for predictive testing. In Fig. 5 panel (A), experimental data from 
two different data sets from rabbit ventricular myocytes are shown in drug free conditions 
(left), and also following the application of 3 nM ATX-II (middle) as well as with combined 
3 nM ATX-II with 0.3 μM GS-458967 application (right). Panel (B) shows the predicted 
effects of these same conditions in the virtual rabbit ventricular myocyte population 
constructed by randomly vary the amplitude of maximal conductances for INa, ICaL, IKs, IKr, 
IK1, Ito, INaK, INaCa to within (±) 10% of their nominal values in the rabbit ventricular 
myocyte model at a steady pacing frequency of 0.2 Hz with drug free (left), simulated effect 
of ATX-II (middle) and combined application of GS-458967 0.3 μM with ATX-II (right). 
This pattern of results clearly shows the same low concentration of GS-458967 is predicted 
to normalize the potent effect of ATX-II to prolong APD in the experiment and simulation 
(Table 2).
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Having established that a reduction of INaL (by GS-458967) can be protective against APD 
prolongation during exposure to ATX-II, we focused on the effect of GS-458967 to 
normalize QT interval prolongation and reduce spatial dispersion of repolarization following 
application of ATX-II. Fig. 6 shows membrane potential space-time plots and simulated 
electrograms (lower) computed using a one-dimensional 165-rabbit ventricular myocyte 
transmural cardiac strand preparation. Panel A shows the effect of application of ATX-II 
alone during a short-long-short (S1-S2-S1) pacing protocol. Notice that ATX-II causes high 
amplitude T-waves on the computed electrograms following application of the S2. This is an 
indication of spatial APD dispersion. In (B), the effects of 0.03 μM GS-458967 both reduces 
QT interval prolongation and diminishes spatial APD dispersion as indicated by the marked 
reduction in T-wave amplitude. Panel (C) shows that an increase in GS-458967 
concentration to 0.1 μM further reduced QT interval prolongation. The higher concentration 
of GS-458967 also reversed the repolarization gradient. This is illustrated by inversion of the 
T-wave. This effect is a result of repolarization of the endocardial myocytes before the 
epicardial myocytes. This is due to the larger effect of block of INaL on the background of 
smaller repolarizing currents intrinsic to the endocardial cells.
3.3. Reduction of INaL by GS-458967 reduces all proarrhythmia-linked parameters in the 
TRIaD
Detailed assessment of the effects of GS-458967 on the proarrhythmia parameters that form 
the TRIaD, systematic simulations to track each parameter were done (i) in the drug free 
control conditions, (ii) in the presence of dofetilide and (iii) with a combination of dofetilide 
and GS-458967. The results are shown in Fig. 7.
The effects of GS-458967 to improve temporal action potential duration dispersion were 
assessed first. We conducted a “computational experiment” using a myocyte sample 
consisting of 1000 action potentials generated after incorporating physiological noise [31] 
[23,32]. This produces quite pronounced beat-to-beat variability at 1 Hz pacing rate as 
shown in Fig. 7 (A) the drug-free control case (mean = 214.76 ms, standard deviation = 4.17 
ms), (B) following simulated application of the IKr blocker dofetilide (16 nM) (mean = 
256.27 ms, standard deviation = 6.89 ms) and (C) predicted effects of 0.3 μM GS-458967 
with dofetilide 16 nM (mean = 236.87 ms, standard deviation = 5.24 ms). The noisy current 
was generated as described in [23] and in the Methods. Following pacing to steady-state at a 
stimulation frequency of 1 Hz, the physiological noise was applied throughout the duration 
of the ensuing simulation of 1000 paced beats. The action potentials for each beat during 
this noise protocol were recorded.
We next predicted the extent of action potential triangulation in silico as a function of APD 
prolongation in the myocyte population as described above for Fig. 7A–C. In Fig. 7 control 
(slope = 0.37) is shown in panel D. Panel E shows the effect of dofetilide 16 nM (slope = 
0.52) and in (F) dofetilide 16 nM in combination with GS-458967 0.3 μM (slope = 0.35) is 
shown. Dofetilide increased both the APD90 as indicated by the right shift and increase in 
area of the APD prolongation “cloud” (indicating more APD dispersion). In addition, 
dofetilide increased the triangulation slope, defined as APD90 – APD30. When dofetilide 
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was applied in combination with GS-458967, the model predicted a return to baseline as 
measured by the APD90 “cloud” and a reduction in triangulation.
The effect of the drugs on instability of APD (Fig. 7G) was detected and quantified as the 
difference between the maximum and minimum of 1000 individual cells with physiological 
noise current as a function of prolongation of APD shown in Fig. 7 panels A–C.
The beat-to-beat instability of rabbit ventricular myocyte action potential duration was 
assessed based on the sensitivity of virtual myocytes to small electrical perturbations before 
and after the application of drugs. A small inward current (between 0.1 and 0.2 pA/pF for 50 
ms) was applied randomly during the AP plateau between 10–210 ms after AP initiation. 
Fig. 7H are Poincaré plots of sequential APD pairs indicating the beat-to-beat instability for 
each case. For the control case, shown in black, the mean APD90 was 219.17 ms and the 
standard deviation was 4.75 ms, whereas the max and min APD90 was 231.17 ms and 
213.49 ms, respectively. The case for dofetilide 16 nM is shown in red with (mean = 263.31 
ms, standard deviation = 7.67 ms, max APD90 = 282.25 ms, min APD90 = 252.37 ms). The 
case for dofetilide 16 nM in combination with 0.1 μM GS-458967 is shown in green and has 
APD90 values as follows: mean = 242.91 ms, standard deviation = 6.12, max = 257.92 ms, 
min APD90 = 232.33 ms. In blue is the effect of a higher concentration of GS-458967 (0.3 
μM) in combination with 16 nM dofetilide resulting in a mean APD90 of 230.41 ms, 
standard deviation of 4.84, max and min APD90 = 242.76 ms and 222.47 ms, respectively.
Lastly, as shown in Fig. 7I, the potential for GS-458967 to decrease reverse use dependence 
induced by dofetilide was evaluated. The action potential adaptation curves were generated 
using APD90 values from myocytes at steady-state at the indicated pacing frequencies. 
When dofetilide (red) was applied, there was a clear steepening of the APD adaptation curve 
compared to the baseline drug-free case (black). GS-458967 at 0.1 μM (green) flattened the 
curve, and the application of the higher dose of 0.3 μM of GS-458967 (blue) had a marked 
effect caused mainly by reducing the slow rate dependent APD prolongation.
Arrhythmia can be considered a fundamental emergent spatial phenomenon. Accordingly, 
simulations to determine whether GS-458967 could prevent reentrant arrhythmias in the 
setting of an in silico acquired Long-QT Syndrome were performed. In this study a two-
dimensional heterogeneous anisotropic rabbit ventricular in silico tissue composed of (5 cm 
× 5 cm) myocytes was employed (Fig. 8). Simulations were conducted using a paired 
stimulus (S1-S2) protocol where the S2 was applied (following 200 paced beats initiated 
along the left endocardial edge of the tissue) following the preceding S1 in the computed 
vulnerable window for reentry. Time snapshots are shown on the left for phase maps [33]. 
These maps were constructed following the last planar wave (S1) (first panel) and 
throughout termination of the most persistent wave after S2 (last panel). Membrane voltages 
are indicated by the color gradient. The corresponding pseudo-ECGs are shown in the right 
panels. Panel A in Fig. 8 illustrates the control or drug-free baseline condition. In the 
absence of any drug, there was no persistent reentry. In panel (B) the effect of ATX-II is 
shown, which promoted a persistent reentrant arrhythmia. Panel (C) shows that ATX-II 
combined with 0.3 μM GS-458967 prevented the persistent reentry observed with ATX-II 
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alone. When 16 nM dofetilide was applied (panel D), persistent reentry was induced, but this 
was prevented by co-treatment with 0.3 μM GS-458967 (panel E).
4. Discussion
Recently, new chemical entities (NCEs) have been developed that specifically target the 
slowly inactivating component of the cardiac Na current, that is, the late Na current (INaL). 
Such compounds are now being evaluated as therapeutics in inherited and acquired cardiac 
diseases [34–40]. One promising preclinical candidate first described in 2013 is GS-458967. 
GS-458967 specifically and potently inhibits INaL (IC50 for INaL = 130 nM) [9].
In order to begin to understand the potential for selective inhibition of INaL to mitigate 
arrhythmia risk associated with acquired Long-QT Syndrome, we have utilized experimental 
data describing the kinetics of the cardiac Na+ channel in rabbit ventricular cells models in 
order to modify the Soltis-Saucerman model of the rabbit ventricular myocyte action 
potential model. We then modeled the interaction of GS-458967 with the rabbit Na+ channel 
and the concentration-dependent effect of this novel preclinical compound to affect 
electrophysiological parameters in rabbit cells. Results of the simulations were in good 
agreement with experimental findings with both approaches showing potent concentration-
dependent reduction in INaL and action potential duration. In these experiments and model 
simulations, GS-458967 did not affect myocyte excitability or conduction velocity in 
ventricular tissues, respectively [9]. Although INaL is small compared to peak (INapeak) (∼1–
3%), the magnitude of this current is similar to that of other currents that are active during 
the action potential plateau phase, including IKr, the rapidly activated component of the 
delayed rectifier K+ current.
Abnormal cardiac electrophysiological activity is a common effect caused by block of 
hERG, the alpha subunit of IKr. Block of hERG leads to prolongation of the QT interval on 
the ECG, a phase of the cardiac cycle that corresponds to ventricular cell repolarization. 
Prolongation of the QT interval and proarrhythmia have been so strongly associated that the 
QT interval has become widely used as a surrogate marker for arrhythmia risk. Since 2005, 
the regulatory process for clinical drug candidates includes a dedicated clinical study in 
healthy volunteers, the so-called “Thorough QT Study”. A drug that causes greater than 5 
ms QT prolongation above normal in healthy humans triggers a “regulatory concern”. In the 
present work, we asked the question, “Can we mitigate the risk of QT prolonging 
proarrhythmic drugs with targeted adjunctive therapy by the INaLinhibitor GS-458967”. In 
the current study, we undertook a combined modeling and experimental approach in an 
attempt to improve the rationale for predictive Cardiac Safety Pharmacology.
One way to prevent acquired Long-QT based arrhythmias is to screen and eliminate 
compounds that fail the Thorough QT test. An alternative solution is to identify derivative 
analogs of promising drugs that can retain therapeutic efficacy with reduced hERG block 
[41,42,43,44]. Another approach is to capitalize on the well-known fact that most effective 
antiarrhythmic drugs are “dirty” - they exhibit multiple channel effects [8]. By co-
administering or co-formulating a specific INaL blocker in the setting of unintended hERG 
block, it may be possible to create a situation of “virtuous promiscuity”, where the two drug 
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effects counter each and thus reduced or eliminate electrophysiological abnormalities, 
including prolongation of the action potential duration (APD) and lengthening of the QT 
interval [8,[45].
There is substantial precedent for the empirical mixing and matching of drugs to mitigate 
risk or reduce side effects [45,7]. Moreover, it is notable that the most successful on-market 
antiarrhythmic drugs exhibit multiple off-target or “dirty” effects. Examples include 
amiodarone, dronedarone and verapamil [1,2]. Here, we have expanded this concept in an 
attempt to develop a way to inform and predict the therapeutic benefit of mixing drugs to 
mitigate cardiotoxic side effects. We have focused on the common example of unintended 
hERG based cardiotoxicity. Our model predicts substantial reduction of all acquired Long-
QT proarrhythmia-linked parameters through adjunctive administration using GS-458967 to 
specifically inhibit INaL and “cancel” or diminish the effect of hERG block.
We tested the potential for targeted inhibition of INaL by GS-458967 to improve cardiac 
safety in the setting of acquired long-QT Syndrome induced by dofetilide. Dofetilide is a 
prototype of the proarrhythmic class - associated with hERG block, QT prolongation and 
TdP [46]. We recently developed a detailed kinetically based model of the hERG blocker 
dofetilide by extending the consensus five-state Markov chain model that includes three 
closed states (C3, C2 and C1), a conducting open state and (O) an inactivation state (I) 
[22,47,48,49]. This expanded IKr model that includes dofetilide interactions was 
incorporated into the Soltis-Saucerman rabbit ventricular action potential (AP) models [28]. 
Dofetilide has a distinct structure activity relationship that underlies drug-channel interaction 
kinetics that promotes the TRIaD: Triangulation, reverse use dependence, beat-to-beat 
instability of action potential duration, temporal and spatial action potential duration 
dispersion. Thus, we simulated the effects of dofetilide as a “positive control” against which 
we could systematically predict effects of GS-458967 on each parameter of the TRIaD 
linked proarrhythmia.
In our previous study [13], we carried out a simulation showing the effects of GS-458967 
application on Na loading at different frequencies. We also showed the effect of the nominal 
changes to intracellular Na concentration on the amplitudes of the NCX and NaK currents 
during the action potential. These effects were minimal. Our results are not surprising. 
Previous studies have suggested that even pathological increases in late INa are not sufficient 
to account for substantial Na loading and that other mechanisms must also be contributing to 
Na loading during pathological states like heart failure [50,51,11].
There is a critical need to identify a more efficient and better approach for preclinical drug 
screening that is both specific and sensitive, and that also identifies actual “proarrhythmia”, 
rather than surrogate markers [52]. Here, we applied a multiscale modeling approach based 
on experimentally determined drug-channel interactions and kinetics intended to predict 
drug safety or electro-toxicity in the heart. Electrophysiological measurements were used to 
inform the kinetic parameters for functional scale Markov models of drug interactions with 
cardiac ion channels. Drug-channel models were then integrated into virtual cardiac cell and 
tissue level models to predict emergent drug effects to promote specific elements of the 
TRIaD, comprising the proarrhythmia markers that emerge at cell and tissue levels. 
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Experiments were then used to test and validate the predictions of the model. Such a 
combined analysis could be used along with the proposed early QT assessment [53] in order 
to replace the so-called thorough QT study.
We suggest that the in silico TRIaD analysis performed here may be useful to finally 
remove some of the “art” that has been implicit in defining experimental conditions and 
ensuing tests that have been used to provoke arrhythmic responses [54]. Not only does the 
systematic application of the TRIaD tests allow the tracking of numerous proarrhythmic 
parameters, this approach also accounted for cell-to-cell variability and physiological noise 
that likely contribute to the random and rare amalgam of conditions that must be 
concomitantly present to allow a rare arrhythmia event to occur. The in silico screen 
presented in this study can be readily expanded with low cost and high efficiency to 
comprehensively examine any number of arrhythmia provoking conditions or additional 
electrophysiological parameters for preclinical drug testing.
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Fig. 1. 
A comparison of experimentally recorded and model generated transmembrane ion currents 
from rabbit ventricular myocytes. (A) Experimentally measured IKr (upper) [55], and IK1 
(lower) [14]. (B) Simulated IKr (upper) and IK1 (lower) compared. (C) Experimental action 
potential clamp waveform (upper) and corresponding L-type Ca2+ current (lower) from 
rabbit ventricular myocyte [56]. (D) Simulated rabbit ventricular myocyte action potential 
and model generated L-type Ca2+ current. (E) Experimentally recorded Ca2+ transient 
during the AP [15]. (F) Corresponding simulated Ca2+ transient.
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Fig. 2. 
Experimental (symbols) and model optimized (lines) drug free Na+ current parameters in a 
rabbit ventricular myocyte. (A) Na+ current activation curve derived from data generated in 
response to depolarizing voltage clamp pulses [18]. (B) Steady-state inactivation [18]. (C) 
Recovery from inactivation at −100 mV [18]. (D) INa waveform in drug free conditions at 
low gain normalized to peak current [9]. (E) Drug free INa at high gain [9]. (F) 
Superimposition of model predicted and experimentally recorded drug free or baseline INa in 
response to a slow depolarizing ramp voltage protocol.
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Fig. 3. 
Experimentally measured and model predicted effect of GS-458967 on INa in rabbit 
ventricle. (A) Optimized model generated concentration-dependent data for GS-458967 on 
late Na current compared to two separate sets of experimental data - Blue asterisks indicate 
experimental data set #1 (n = 4) [9], and red circles are from experimental data set #2 (For 0 
μM and 0.03 μM, n = 3. For 0.1 μM and 0.3 μM, n = 4. For 1 μM, n = 6. For 3 μM, n = 2). 
The effect of high concentration GS-458967 on peak INa is indicated for experiments (blue 
square), and simulated INa peak (black triangle). (B) Behavior of a myocyte ‘population’ 
was simulated by randomly varying the amplitude of maximal conductances for INa, ICaL, 
IKs, IKr, IK1, Ito, INaK, INaCa (to within 10% of their nominal values in the rabbit ventricular 
myocyte model). This approach allowed for efficient analysis of 100 distinct cell action 
potentials. APD90 was calculated at 1 Hz for each case. These simulated myocyte properties 
were compared to experimental data set #1 (blue asterisks) and experimental data set #2 (red 
circles).
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Fig. 4. 
In silico prediction of GS-458967 induced reduction of INaL and concentration-dependent 
shortening of APD in rabbit ventricular myocytes. (A) Simulated effects of GS-458967 on 
rabbit ventricular myocyte AP and (B) the corresponding effects of GS-458967 on late INa.
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Fig. 5. 
GS-458967 can effectively attenuate APD prolongation by ATX-II in rabbit ventricular 
myocytes. (A) Experimental data from two distinct data sets from rabbit ventricular 
myocytes showing drug free conditions (left), the effect of 3 nM ATX-II (middle) and the 
combination of 3 nM ATX-II with 0.3 μM GS-458967 (right). (B) Simulated effects on 
virtual rabbit ventricular myocyte showing drug free (left), simulated effect of ATX-II 
(middle) and ATX-II with co-treatment with GS-458967 0.3 μM (right).
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Fig. 6. 
Simulations showing that GS-458967 can effectively reduce spatial APD dispersion caused 
by ATX-II. (A) Space-time plots of membrane potential (top) and pseudo ECGs (lower) 
computed from a 165-rabbit myocyte transmural cardiac preparation in the presence of 
ATX-II during a “short-long-short” pacing protocol. (B) 0.03 μM GS-458967 markedly 
diminishes QT interval prolongation and APD dispersion as indicated by reduced T-wave 
amplitude. (C) 0.1 μM GS-458967 further reduced QT interval prolongation and reversed 
the repolarization gradient as demonstrated by inversion of the T-wave.
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Fig. 7. 
In silico pharmacological results suggesting that GS-458967 can reduce all proarrhythmia-
linked parameters set out in the TRIaD approach: Triangulation, reverse use dependence, 
beat-to-beat instability of action potential duration, as well as temporal and spatial action 
potential duration dispersion. Predicted temporal action potential duration dispersion of 
1000 simulated myocyte action potentials generated after incorporating physiological noise 
to induce beat-to-beat variability at 1 Hz in (A) the drug-free control case, (B) effects of 
simulated application of the IKr blocker Dofetilide (16 nM) and (C) predicted effects of 0.3 
μM GS-458967 with Dofetilide 16 nM. Action potential triangulation as a function of APD 
prolongation for individual myocytes for (D) control (slope = 0.37), (E) Dofetilide 16 nM 
(slope = 0.52) and (F) Dofetilide 16 nM + GS-458967 0.3 μM (slope = 0.35). (G) Instability 
of APD was quantified as the difference between the maximum and minimum of 1000 
individual myocytes in the presence of physiological noise current as a function of 
prolongation of APD (shown in panels A–C). (H) Simulated beat-to-beat instability of 
rabbit ventricular myocyte action potentials to small perturbations before and after 
application of drugs. Poincaré plots of sequential APD pairs indicating beat-to-beat 
instability are shown for each case. (I) GS-458967 improved dofetilide induced reverse use 
dependence: Action potential adaptation curves show APD90 at various pacing frequencies 
in the presence or absence of drugs.
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Fig. 8. 
GS-458967 can prevent spiral wave reentry in the setting of acquired Long-QT Syndrome. A 
two-dimensional simulated heterogeneous anisotropic rabbit ventricular tissue was activated 
using a paired stimulus (S1-S2) protocol. (A) Shows the control or drug-free case, (B) with 
ATX-II, (C) with ATX-II and 0.3 μM GS-4589677, (D) 16 nM Dofetilide, or (E) 16 nM 
Dofetilide and 0.3 μM GS-458967. Tissues (5 cm × 5 cm) were stimulated (S1) along left 
edge (endocardium) and this followed by a premature stimulus (S2) applied in the 
vulnerable window (see Methods). Six snapshots obtained following application of 
GS-458967, dofetilide or both at selected time points. Corresponding pseudo-ECGs are in 
the right panels. Membrane voltage values are indicated by the color gradient.
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Table 1
Current density changes in cardiac ventricular cell model: the maximum conductances were tuned to 
approximate the experimentally measured current amplitudes during the action potential. An action potential 
duration that was within the experimental range was determined.
Ionic parameters Scaling factors
pCa 0.7
Gtoslow 1.3
Gtofast 1.3
GK1 0.5
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Table 2
Simulated and experimental measured APD90: To simulate enhancement of late INa with ATX-II, rate 
constant, μ2, was reduced by 40%.
BCL = 5000 ms Fig. 5 Experimental APD90 (ms) (mean values) Simulated APD90 (ms) (mean values from 1000 APs)
Cell 1 Cell 2
Control 258.8 (n = 11) 522 (n = 6) 240.91
ATX-II 625.2 (n = 10) 2305.2 (n = 12) 497.02
Relative change to ATX-II 58.6% 77.3% 51.53%
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